PFE vs. REGN: Pfizer vs. Regeneron Pharmaceuticals Stock Comparison

Company Profile

Pfizer (PFE) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PFE is classified in Pharmaceuticals while REGN is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Regeneron Pharmaceuticals (REGN) sees a more moderate 772.95K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for REGN.

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

Both Pfizer (PFE) at 33.38% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Regeneron Pharmaceuticals (REGN) at 0.99% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both Pfizer (PFE) at -3.55% and Regeneron Pharmaceuticals (REGN) at 8.19% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

Regeneron Pharmaceuticals (REGN) at 0.08 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Pfizer (PFE) at 7.30% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Regeneron Pharmaceuticals (REGN) reports 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Pfizer (PFE) at 41.99 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Pfizer (PFE) at 1.88 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics